FDA Needs More Up-to-Date Information Before Finalizing COVID-19 Vaccines for 2024-2025

The U.S. Food and Drug Administration (FDA) today announced on X a change of date for its May 16, 2024, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting.

The VRBPAC is now scheduled to meet on June 5, 2024, to recommend the inclusion of the SARS-CoV-2 coronavirus strain(s) in the 2024-2025 COVID-19 vaccines.

@FDACBER stated the VRBPAC will have more up-to-date information when discussing and making recommendations.

This advisory committee provides independent expert advice to the FDA on broad scientific topics or certain products to help the agency make sound decisions based on the available science. 

As of 2024, about 50 COVID-19 vaccines have been approved globally since the pandemic began in late 2019. SKYCovione™ became the 12th, and CORBEVAX®  the 13th COVID-19 vaccine granted authorization by the WHO.